GLP-1 Receptor in Pancreatic α-Cells Regulates Glucagon Secretion in a Glucose-Dependent Bidirectional Manner
Open accessThe DOI matches its Crossref record; 42 of the 43 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide 1 (GLP-1) is known to suppress glucagon secretion, but the mechanism by which GLP-1 exerts this effect is unclear. In this study, we demonstrated GLP-1 receptor (GLP-1R) expression in α-cells using both antibody-dependent and antibody-independent strategies. A novel α-cell–specific GLP-1R knockout (αGLP-1R−/−) mouse model was created and used to investigate its effects on glucagon secretion and glucose metabolism. Male and female αGLP-1R−/− mice both showed higher nonfasting glucagon levels than their wild-type littermates, whereas insulin and GLP-1 levels remained similar. Female αGLP-1R−/− mice exhibited mild glucose intolerance after an intraperitoneal glucose administration and showed increased glucagon secretion in response to a glucose injection compared with the wild-type animals. Furthermore, using isolated islets, we confirmed that αGLP-1R deletion did not interfere with β-cell function but affected glucagon secretion in a glucose-dependent bidirectional manner: the αGLP-1R−/− islets failed to inhibit glucagon secretion at high glucose and failed to stimulate glucagon secretion at very low glucose condition. More interestingly, the same phenomenon was recapitulated in vivo under hypoglycemic and postprandial (fed) conditions. Taken together, this study demonstrates that GLP-1 (via GLP-1R in α-cells) plays a bidirectional role, either stimulatory or inhibitory, in glucagon secretion depending on glucose levels.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“GLP-1 also inhibits glucagon release from α-cells, which is beneficial for reducing blood glucose levels since glucagon promotes hepatic gluconeogenesis.131,225”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [131]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Research indicates that the expression level of GLP-1R on α-cells is relatively low.131”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [131]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adult insulin- and glucagon-producing cells differentiate from two independent cell lineages
Herrera, P. L. (2000) · Development · doi:10.1242/dev.127.11.2317 · Cited by 672
α-Cells of the Endocrine Pancreas: 35 Years of Research but the Enigma Remains
Gromada, J., Franklin, I., & Wollheim, C. B. (2007) · Endocrine Reviews · doi:10.1210/er.2006-0007 · Cited by 581 · cited 1×
“Under normal conditions, glucagon secretion is highly responsive to glucose variations: glucagon secretion is minimal when the glucose level is 6–10 mmol/L, increases when glucose is 3–6 mmol/L, and is maximally stimulated when glucose is 2–3 mmol/L (31).”
BackgroundRichards, P., Parker, H. E., Adriaenssens, A. E., Hodgson, J. M., Cork, S. C., Trapp, S., Gribble, F. M., & Reimann, F. (2014) · Diabetes · doi:10.2337/db13-1440 · Cited by 472 · cited 4×
“The controversy on GLP-1R expression in a-cells was largely attributable to the use of different antibodies or different methods (7,8,10,30).”
BackgroundMethodInfluentialNauck, M. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12591 · Cited by 429
ØRSKOV, C., HOLST, J. J., & NIELSEN, O. V. (1988) · Endocrinology · doi:10.1210/endo-123-4-2009 · Cited by 396 · cited 1×
“However, this indirect hypothesis cannot explain the facts that the glucagonostatic effect of GLP-1 is present even when insulin is unstimulated (15,16) or in patients with type 1 diabetes with no residual b-cells (17,18).”
BackgroundPanjwani, N., Mulvihill, E. E., Longuet, C., Yusta, B., Campbell, J. E., Brown, T. J., Streutker, C., Holland, D., Cao, X., Baggio, L. L., et al. (2013) · Endocrinology · doi:10.1210/en.2012-1937 · Cited by 346 · cited 3×
“To make the topic even more complicated, studies have reported that the commonly used anti–GLP1R antibodies are neither specific nor sensitive enough to reliably detect GLP-1R expression in tissues (1,12).”
BackgroundCreutzfeldt, W. O. C., Kleine, N., Willms, B., Ørskov, C., Holst, J. J., & Nauck, M. A. (1996) · Diabetes Care · doi:10.2337/diacare.19.6.580 · Cited by 330 · cited 2×
“However, this indirect hypothesis cannot explain the facts that the glucagonostatic effect of GLP-1 is present even when insulin is unstimulated (15,16) or in patients with type 1 diabetes with no residual b-cells (17,18).”
BackgroundResultIncretin Action in the Pancreas: Potential Promise, Possible Perils, and Pathological Pitfalls
Drucker, D. J. (2013) · Diabetes · doi:10.2337/db13-0822 · Cited by 272 · cited 4×
“To make the topic even more complicated, studies have reported that the commonly used anti–GLP1R antibodies are neither specific nor sensitive enough to reliably detect GLP-1R expression in tissues (1,12).”
BackgroundInfluentialAlpha cell function in health and disease: influence of glucagon-like peptide-1
Dunning, B. E., Foley, J. E., & Ahrén, B. (2005) · Diabetologia · doi:10.1007/s00125-005-1878-0 · Cited by 271 · cited 1×
“Numerous studies have demonstrated that GLP-1 is a potent and physiological inhibitor of glucagon secretion (5,6).”
BackgroundParacrinology of islets and the paracrinopathy of diabetes
Unger, R. H., & Orci, L. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1006639107 · Cited by 269 · cited 1×
“insulin—GLP-1 stimulates insulin secretion from b-cells, which subsequently suppress glucagon secretion because insulin is a powerful inhibitor of glucagon secretion (13,14).”
Background
Cited by
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
“131,225 GLP-1 ’ s action on α -cells regulates glucagon release.”
BackgroundInfluentialRevisiting the Complexity of GLP-1 Action from Sites of Synthesis to Receptor Activation
McLean, B. A., Wong, C. K., Campbell, J. E., Hodson, D. J., Trapp, S., & Drucker, D. J. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnaa032 · Cited by 289
“13 reporter mouse line, detected GLP-1R throughout the -cell and α-cell cytoplasm (45).”
BackgroundIncretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence
Alicic, R. Z., Cox, E. J., Neumiller, J. J., & Tuttle, K. R. (2021) · Nature Reviews Nephrology · doi:10.1038/s41581-020-00367-2 · Cited by 193
Antidiabetic agents as a novel treatment for Alzheimer’s and Parkinson’s disease
Nowell, J., Blunt, E., Gupta, D., & Edison, P. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.101979 · Cited by 179
“Regulation of glucagon secretion by pancreatic α -cells β cells whilst increasing insulin biosynthesis and pancreatic β cell proliferation, in a glucose-dependent manner, are additional effects of this drug class shown in rodents (Zhang et al., 2019).”
Background
Metadata
- Authors
- Zhang, Y., Parajuli, K. R., Fava, G. E., Gupta, R., Xu, W., Nguyen, L. U., Zakaria, A. F., Fonseca, V. A., Wang, H., Mauvais-Jarvis, F., Sloop, K. W., & Wu, H.
- Affiliations
- Tulane University (US)
- Medical University of South Carolina (US)
- Section of Endocrinology, Department of Medicine, Tulane University Health Science Center, New Orleans, LA
- Eli Lilly (United States) (US)
- Corresponding author
- Wu, Hongju
- ORCID
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2018-11-02
- Volume
- 68
- Issue
- 1
- Pages
- 34-44
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC6302540
- OpenAlex
- W2899183711
- Semantic Scholar
- ac8cb7167621574489ce0bd5c237f46e94084811
- Cited by
- 104
- References
- 43
- Citations by year
- 2026: 10 · 2025: 20 · 2024: 17 · 2023: 15 · 2022: 5 · 2021: 16 · 2020: 14 · 2019: 7
- FWCI
- 6.86
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Diabetes (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Susan Harling Robinson Fellowship in Diabetes research
- National Institute of Diabetes and Digestive and Kidney Diseases (DK-081463, DK-107412, R01-DK-074970, DK-107444)
- U.S. Department of Veterans Affairs VA Merit Review Award (BX003725)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Keywords
- GLP-1 receptor, glucagon secretion, alpha cells, bidirectional regulation, impaired glucose tolerance, hypoglycemia, islet function, beta-cell function, glucose metabolism
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Animals, Female, Flow Cytometry, Glucagon, Glucose, Glucose Tolerance Test, Immunohistochemistry, Mice, Knockout, Reverse Transcriptase Polymerase Chain Reaction, Glucagon-Secreting Cells, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: GLP-1 Receptor in Pancreatic α-Cells Regulates Glucagon Secretion in a Glucose-Dependent Bidirectional Manner. https://app.cochat.ai/papers/10.2337/db18-0317
- The paper
- Zhang, Y., Parajuli, K. R., Fava, G. E., Gupta, R., Xu, W., Nguyen, L. U., Zakaria, A. F., Fonseca, V. A., Wang, H., Mauvais-Jarvis, F., Sloop, K. W., & Wu, H. (2019). GLP-1 Receptor in Pancreatic α-Cells Regulates Glucagon Secretion in a Glucose-Dependent Bidirectional Manner. Diabetes. https://doi.org/10.2337/db18-0317
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.